

MICRUS ENDOVASCULAR CORP

Form 8-K

November 13, 2006

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934  
Date of Report (Date of Earliest Event Reported): November 13, 2006**

**Micrus Endovascular Corporation**  
(Exact name of registrant as specified in its charter)  
**000-51323**  
(Commission File Number)

**Delaware**  
(State or Other Jurisdiction of  
Incorporation)

**23-2853441**  
(I.R.S. Employer Identification No.)

**821 Fox Lane**  
**San Jose, California 95131**  
(Address of principal executive offices, including zip code)  
**(408) 433-1400**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 2.02. Results of Operations and Financial Condition.

Item 9.01. Financial Statements and Exhibits.

SIGNATURE

EXHIBIT INDEX

EXHIBIT 99.1

---

**Table of Contents**

**Item 2.02. Results of Operations and Financial Condition.**

On November 13, 2006, Micrus Endovascular Corporation ( Micrus ) issued a press release, reporting its financial results for the fiscal quarter ended September 30, 2006. A copy of this earnings release is attached as Exhibit 99.1 hereto. Following the issuance of this earnings release, Micrus hosted an earnings call in which its financial results for the fiscal quarter ended September 30, 2006 were discussed.

Exhibit 99.1 contains forward-looking statements within the meaning of the federal securities laws. These statements are present expectations, and are subject to the limitations listed therein and in Micrus' other SEC reports, including that actual events or results may differ materially from those in the forward-looking statements.

The foregoing information (including the exhibit hereto) is being furnished under Item 2.02 Results of Operations and Financial Condition (including the exhibit hereto) and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

<b><u>Exhibit</u></b>	<b><u>Description</u></b>
99.1	Press Release dated November 13, 2006

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MICRUS ENDOVASCULAR  
CORPORATION  
(Registrant)

Date: November 13, 2006

By: /s/ Robert A. Stern  
Robert A. Stern  
Executive Vice President, Chief  
Financial  
Officer, and Secretary

-2-

---

**Table of Contents**

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release dated November 13, 2006

-3-